|
1000
|
Abstract/Summary
|
-
Little is known about antibody development after SARS-CoV-2 vaccination in immunocompromised individuals, such as patients with cancer. The presented retrospective cohort study included two independent cohorts of patients who were treated for hematooncological diseases between October 2020 and May 2021. Serum samples were collected from patients who were treated for cancer and a control group of HCWs, all of whom received SARS-CoV-2 vaccination. Total anti–SARS-CoV-2 nucleocapsid and antispike protein antibodies were measured retrospectively. In this cohort study of patients with hematooncological diseases and a control group of HCWs, antibody levels were compared and differences in seroconversion in specific subgroups were analysed. An outlook on ongoing follow-up projects will be provided. VACCELERATE, the EU funded clinical research network for the coordination & conduct of COVID-19 vaccine trials is looking forward to hosting this webinar.
|
